Journal: International Dental Journal

Article Title: Obesity as a Determinant of Periodontal Therapy Outcomes: Insights on Oxidative and Endoplasmic Reticulum Stress Pathways

doi: 10.1016/j.identj.2026.109472

Figure Lengend Snippet: Oxidative stress markers in the study population, stratified by obesity presence, before and after non-surgical periodontal treatment. Total ROS (A and G), cytosolic superoxide (B and H) and mitochondrial superoxide (C and I) in leukocytes, and protein levels of SOD1 (D and J) in PBMCs normalized to the loading control actin with corresponding WB images (E), and serum total antioxidant capacity (F and K). Data are presented as box and whisker plots and were compared using two-factor analysis of variance (ANOVA) followed by post hoc tests. ** P < .01 when comparing baseline vs 12 wk. # P < .05 when comparing groups with vs without obesity. DCFH, diclorodihidrofluoresceína; dHE, dihydroethidium; MitoSOX, Mitochondrial Superoxide Indicator; ns, not significant; PBMCs, peripheral blood mononuclear cells; ROS, reactive oxygen species; SOD1, superoxide dismutase 1.

Article Snippet: Peripheral blood mononuclear cells (PBMCs) comprising monocytes and lymphocytes were isolated from EDTA-collected blood using the MACSprep PBMC Isolation Kit (Miltenyi Biotec, Teterow, Germany), and 5 × 106 cells were used for protein extraction, quantification, and Western blot (WB) analysis.

Techniques: Control, Whisker Assay

Journal: International Dental Journal

Article Title: Obesity as a Determinant of Periodontal Therapy Outcomes: Insights on Oxidative and Endoplasmic Reticulum Stress Pathways

doi: 10.1016/j.identj.2026.109472

Figure Lengend Snippet: Evaluation of UPR markers in PBMCs from study population, stratified by presence of obesity, before and after non-surgical periodontal treatment. Relative protein expression of GRP78 (A and G), ATF6 (B and H), CHOP (C and I), IRE1α (D and J), p-eIF2α (E and K), relative mRNA expression of sXBP1 (F and L) in PBMCs normalized to the loading control actin and representative WB images (M). Data are presented as box and whisker plots and were compared using two-factor analysis of variance (ANOVA) followed by post hoc tests. * P < .05; ** P < .01 when comparing baseline vs 12 wk. ATF6, activating transcription factor 6; BMI, body mass index; CHOP, C/EBP homologous protein; GRP78, Glucose-regulated protein 78; IRE1α, Inositol requiring enzyme 1α; PBMCs, peripheral blood mononuclear cells; p-eIF2α, Phosphorylated eukaryotic translation initiation factor 2 subunit; sXBP1 , spliced Xbox binding protein 1 gene.

Article Snippet: Peripheral blood mononuclear cells (PBMCs) comprising monocytes and lymphocytes were isolated from EDTA-collected blood using the MACSprep PBMC Isolation Kit (Miltenyi Biotec, Teterow, Germany), and 5 × 106 cells were used for protein extraction, quantification, and Western blot (WB) analysis.

Techniques: Expressing, Control, Whisker Assay, Binding Assay

Journal: NAR Cancer

Article Title: Efficient gene disruption with CRISPR–Cas3 in human T cells

doi: 10.1093/narcan/zcag009

Figure Lengend Snippet: CRISPR–Cas3-engineered CAR-T cells retain cytotoxic function and exhibit reduced alloreactivity. ( A ) Flow cytometric analysis of TCRα/β and HLA–ABC expression in TRAC - or B2M -disrupted versus nondisrupted T cells after magnetic cell sorting. ( B ) CAR expression and residual TCRα/β or HLA–ABC expression in TRAC - or B2M -disrupted versus nondisrupted CAR-T cells assessed by flow cytometry. ( C ) Mixed lymphocyte reaction (MLR) assays evaluating alloreactivity of TRAC -disrupted CAR-T cells cocultured with irradiated allogeneic PBMCs, or B2M -disrupted CAR-T cells cocultured with allogeneic T cells. Data represent mean ± SD from triplicate wells ( n = 3). ( D ) Cytotoxic activity of TRAC - or B2M -disrupted CAR-T cells against GM2-positive or GM2-negative tumor cells (right panels), compared with non-genome-edited CAR-T cells processed under identical conditions (left panels). Data represent mean ± SD from triplicate wells ( n = 3). Statistical significance was determined using unpaired two-tailed Student’s t -test: * P < .05, ** P < .01, *** P < .001.

Article Snippet: Peripheral blood mononuclear cells (PBMCs) were obtained from Charles River Laboratories International, Inc.

Techniques: CRISPR, Expressing, FACS, Flow Cytometry, Irradiation, Activity Assay, Two Tailed Test

Journal: Cell Reports Medicine

Article Title: Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS

doi: 10.1016/j.xcrm.2026.102749

Figure Lengend Snippet: In vivo characterization of Debio 1562M in mice and cytotoxicity assessment in human PBMCs (A) Concentrations of total ADC and total antibody in the plasma of healthy mice were measured over time following i.v. injection with 1 mg/kg Debio 1562M ( n = 3; mean ± SEM). (B) Plasma concentrations of Debio 1562 or Debio 1562M were monitored over time in tumor-bearing mice following i.v. injection with 10 mg/kg of either ADC ( n = 3; mean ± SEM). (C–G) Male and female mice were injected with vehicle (control) or DAR-equivalent doses of Debio 1562 (single dose, 100 mg/kg) or Debio 1562M (every 3 weeks, Q3W ×2, 50 mg/kg doses) ( N ≥ 5; mean ± SEM). (C) Body weights were monitored throughout the experiment. (D) Platelets, (E) WBC counts, and (F) liver enzymes (shown are ALP, alanine transferase [ALT], and aspartate transferase [AST] levels) were measured on day 5 (Debio 1562 experiments), day 11 (Debio 1562M single dosing experiments), or day 23 (Debio 1562M Q3W ×2 dosing); two-way ANOVA p values: ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (G) PBMCs from healthy volunteers were cultured in the presence of vehicle or 1 μM Debio 1562M for 72 h prior to immunophenotyping and assessment of viability. n = 5; mean ± SEM. Two-way ANOVA p values: ∗ p < 0.05, ns: not significant. See also .

Article Snippet: Cryopreserved PBMCs from healthy donors were provided and handled by Eurofins Discovery.

Techniques: In Vivo, Clinical Proteomics, Injection, Control, Cell Culture

Journal: Cell Reports Medicine

Article Title: Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS

doi: 10.1016/j.xcrm.2026.102749

Figure Lengend Snippet:

Article Snippet: Cryopreserved PBMCs from healthy donors were provided and handled by Eurofins Discovery.

Techniques: Recombinant, Proliferation Assay, Antibody Labeling, Software